Mitoguazone
- Generic Name
- Mitoguazone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C5H12N8
- CAS Number
- 459-86-9
- Unique Ingredient Identifier
- OD5Q0L447W
- Background
Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin.
- Associated Conditions
- -
- Associated Therapies
- -
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Phase 3
Terminated
- Conditions
- Interventions
- Biological: bleomycin sulfateDrug: ABVD regimenDrug: cisplatinDrug: carmustineDrug: cytarabineDrug: dacarbazineDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: gemcitabine hydrochlorideDrug: methylprednisoloneDrug: vincristine sulfateDrug: ifosfamideDrug: vindesineDrug: melphalanDrug: mitoguazoneDrug: vinorelbine tartrateProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 442
- Registration Number
- NCT00920153
- Locations
- 🇫🇷
FILO French Innovative Leukemia Organization, Tours Cedex, France
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00002348
- Locations
- 🇺🇸
ILEX Oncology Inc, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath